New to The Street Broadcasts Tonight on Bloomberg at 6:30 PM EST Featuring Roadzen, BioVie, and TY J Young Wealth
AI Sentiment
Highly Positive
8/10
as of 12-05-2025 2:02pm EST
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CARSON CITY |
| Market Cap: | 14.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 71.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $30.90 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
BIVI Breaking Stock News: Dive into BIVI Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how BIVI stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BIVI BioVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.